#functional cure

A new case may provide clues to help researchers develop strategies for a functional cure.

Two Campbell Foundation grantees hope to find out and better understand the HIV reservoir. Their work could help research for a cure.

The study findings underscore the importance of starting antiretroviral therapy as soon as possible.

Two broadly neutralizing antibodies delayed HIV rebound in people who started antiretroviral therapy early.

One person treated with a broadly neutralizing antibody plus romidepsin remained in remission for 3.7 years.

A combination of two antibodies, dubbed 3BNC117 and 10-1074, maintained viral suppression for a year in two people.

Scientists found that latent HIV appeared to increasingly concentrate in inactive regions of the genome.

The woman’s leukemia is in remission and she remains free of detectable HIV more than a year after stopping antiretroviral treatment.

The experimental vaccine regimen aims to train B cells to produce broadly neutralizing antibodies against HIV.

People whose HIV is locked away in “gene deserts” might be able to interrupt treatment without viral rebound.

COVID-19, HIV vaccine and cure news, and long-acting HIV treatment and prevention topped the news again this year.

The updated report summarizes progress to date, identifies gaps and outlines recommendations for HIV cure research over the next five years.

The Esperanza Patient has no evidence of intact HIV blueprints that can produce more virus.

One new approach protects CD4 cells against HIV entry, while another snips out viral genes in infected cells.

Different mechanisms suppressed the virus in each person.

NIH-funded study finds reduced levels of HIV in bone marrow, spleen and brain after nanoparticle therapy.